96 results about "Nicotinic Acids" patented technology

The invention discloses a fermentation medium for regulating and controlling a clostridium aerovorans target product and a fermentation method of the clostridium aerovorans target product. The medium comprises a basic component and a regulating component, the basic components comprise ammonium chloride, potassium chloride, magnesium sulfate heptahydrate, sodium chloride, monopotassium phosphate, yeast powder, calcium chloride dihydrate, sodium selenite, nickel chloride hexahydrate, biotin, folic acid, pyridoxine hydrochloride, thiamine, riboflavin, nicotinic acid, D-calcium pantothenate, cobalamin, para aminobenzoic acid and lipoic acid; the adjusting component comprises sodium tungstate, ferrous sulfate and sodium molybdate, sodium tungstate and ferrous sulfate have a forward adjusting effect on increasing the yield of acetic acid, ethanol and butanol in the target product, and sodium molybdate has a reverse adjusting effect on the target product. By optimizing the proportion of trace elements in the culture medium, the clostridium metabolism efficiency is improved, synthesis of a target product is regulated and controlled, and the method is particularly suitable for industrial production of acetic acid, ethanol, butanol and the like.

The invention relates to a method for preparing a nerofloxacin chiral piperidylamine intermediate, which comprises the following steps of: carrying out condensation reaction on 5-hydroxy nicotinic acid which is simple and easy to obtain and is used as a raw material and different alcohols, screening through a series of asymmetric catalytic hydrogenation conditions to obtain optimal reaction conditions, and under the conditions, carrying out reaction on various 3, 3 '-dihydroxy nicotinic acid and 3, 3'-dihydroxy nicotinic acid to obtain the nerofloxacin chiral piperidylamine intermediate. The 2, 5-disubstituted pyridine quaternary ammonium salt is reduced into a tetrahydropyridine product, and the C5 site enantioselectivity of the product is excellent. The preparation method comprises the following steps: selecting methyl (R)-1-benzyl-5-hydroxy-1, 4, 5, 6-tetrahydropyridine-3-carboxylic acid methyl ester as a substrate, completely hydrogenating by using platinum dioxide hydrogen, and then carrying out methyl ester reduction, dehydroxylation, Mitsunobu reaction and protecting group removal to obtain a key chiral intermediate for industrial synthesis of a quinolone antibacterial drug nemonofloxacin with high enantioselectivity and high yield.

The invention relates to a preparation method of (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane and an intermediate of the (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane. Specifically, the invention discloses a method for preparing (S, S)-2, 8-diazabicyclo [4, 3, 0] nonane from a cheap raw material 2-chloronicotinic acid through an esterification reaction, a substitution reaction, a reduction reaction and an asymmetric hydrogenation reaction, and the method is novel in route, simple to operate, high in product yield, good in purity, safe, environment-friendly and very suitable for industrial production.

The present application relates to a kind of meloxicam benzene sulfonic acid tablets and its preparation method and application, the meloxicam benzene sulfonic acid tablets include stabilizer, the stabilizer is selected from one or more of anhydrous citric acid, polyethylene glycol, sorbitol, crosslinked povidone, sodium acetate trihydrate, anhydrous sodium acetate, nicotinic acid, nicotinamide, polyacrylic acid resin, ascorbic acid palmitate.The stability of meloxicam benzene sulfonic acid tablets prepared according to the prescription of the present application is significantly improved, while the preparation process is simple, and has good application prospect.

The application discloses a glabridin-nicotinamide co-crystal as well as a preparation method and application thereof, belongs to the technical field of co-crystals, and comprises nicotinamide and glabridin molecules. 26 H 26 N2O5, and the molar ratio of the nicotinamide and the glabridin is 1:1.The application prepares a glabridin-nicotinamide co-crystal, and the co-crystal is completely characterized, and it is proved that the co-crystal has certain physical and chemical stability, the stability of the nicotinamide is improved after being made into the co-crystal, and no stimulating substance nicotinic acid is found in the co-crystal stability experiment. The co-crystal is generally neutral, mild and non-irritating, and is naturally suitable for cosmetics or health products.

The application provides a preparation method of a PARP1 inhibitor intermediate, which comprises the following steps: after 6-hydroxy nicotinic acid is reacted with nitric acid, an intermediate shown in formula I is prepared through halogenation reaction, esterification reaction, hydrolysis reaction and the like. The method has low synthesis cost and high product yield, provides a new advantageous process route for synthesis of the PARP1 inhibitor, and has industrialized popularization and application prospects.

The invention relates to the technical field of biological medicines, and discloses an application of N2L in preparation of medicines for preventing and treating obesity and fatty liver, and the N2L is a dimer compound of alpha-lipoic acid and nicotinic acid. According to the embodiment of the invention, the application value of the GPR109A and GLP-1R double-target collaborative strategy in obesity and fatty liver treatment is proposed and verified for the first time, and the small molecule compound N2L with the GPR109A and GLP-1R double-target collaborative strategy can improve muscle endurance while reducing the weight of obese patients and can improve liver fatty degeneration at the same time. The defect that an existing GLP-1R agonist needs to be injected is overcome, meanwhile, the flushing side effect of an existing GPR109A agonist nicotinic acid medicine is avoided, a larger range is provided for medicine selection in the fields of obesity and fatty liver, and meanwhile, the application range of N2L is widened.

The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+:wherein M1, R1, R2, and R3 are as described herein.

The invention discloses a pharmaceutical composition for improving biphasic depression and a pharmaceutical preparation and application thereof, and belongs to the technical field of research and development of biphasic depression drugs, the pharmaceutical composition is composed of nicotine and a second-generation antipsychotic drug, and the second-generation antipsychotic drug is quetiapine or risperidone. Experiments prove that the combined use of the nicotine and the second-generation antipsychotic has a synergistic effect in the aspect of improving the manic behavior of biphasic depression and has a better effect of improving the biphasic depression compared with the independent use of the nicotine and the second-generation antipsychotic.

This invention provides a chemical mechanical polishing (CMP) slurry and its application. The CMP slurry comprises: a catalyst, a stabilizer, an oxidant, a pH adjuster, abrasive particles, a corrosion inhibitor, and water. The corrosion inhibitor is a nitrogen-containing heterocyclic carboxylic acid compound, wherein the nitrogen-containing heterocyclic carboxylic acid compound includes at least one selected from nicotinic acid, isonicotinic acid, pyridinecarboxylic acid, imidazocarboxylic acid, pyrazolecarboxylic acid, 3-pyridineacetic acid, 3-pyridinepropionic acid, 3-methyl-2-pyridinecarboxylic acid, and L-piperidine acid. The CMP slurry provided by this invention can simultaneously polish tungsten and silicon oxide, and can also control the polishing rate of silicon oxide while inhibiting tungsten corrosion, thus making it suitable for different application scenarios. In addition, the CMP slurry has good stability and can maintain its performance even after long-term standing.

The invention relates to the technical field of medicines, in particular to a preparation process of xantinol nicotinate injection and an impurity control method of the xantinol nicotinate injection. According to the process, water for injection is subjected to nitrogen deoxidation treatment, a whole-process nitrogen-sealed environment is maintained, xantinol nicotinate is gradually added in three times, and a multi-component synergistic stable system including hydroxypropyl-beta-cyclodextrin, N-acetyl-L-cysteine, L-methionine, diethylenetriamine pentaacetic acid, sodium metasulfite, sodium thiosulfate and the like is matched, so that the xantinol nicotinate injection is prepared. Double-molecular-weight dextran is introduced to regulate and control a microenvironment, an acetic acid-sodium acetate buffer system is introduced to optimize pH, and finally, high stability and low impurity generation of the finished injection at high temperature are realized through nitrogen replacement subpackaging and precise sterilization conditions. According to the method, the content and the purity of the xantinol nicotinate injection are remarkably improved, the impurity content during sterilization and storage is remarkably reduced, the safety and the effectiveness of drugs are guaranteed, and the method has important significance on optimization of a heat-sensitive injection process.

The invention relates to combination or composition comprising: (i) nicotinic acid or a derivative thereof, and (ii) a fatty acid or a derivative thereof selected from tetradecylthioacetic acid 5 (TTA) or a derivative thereof. The invention further relates to a pharmaceutical or nutritional combination or composition for use in a method of preventing or treating mitochondrial diseases, inflammatory diseases, metabolic disorders, neurodegenerative diseases and / or aging of an animal, and / or a method of increasing brain metabolism of an animal, wherein said pharmaceutical or nutritional 10 combination or composition is administered to said animal, and wherein said pharmaceutical or nutritional combination or composition comprises: (i) nicotinic acid or a derivative thereof, and (ii) a fatty acid or a derivative thereof selected from tetradecylthioacetic acid (TTA) or a derivative thereof.

The invention provides a culture method of human umbilical cord mesenchymal stem cells, and belongs to the technical field of cell culture. The method comprises the following steps: firstly, constructing an activation culture medium aiming at an initial culture stage and an amplification culture medium aiming at an amplification culture stage; wherein the activation culture medium takes alpha-MEM containing 10% of fetal calf serum as a basic culture medium, and alpha-tocopherol, nicotinic acid and gypenoside are added as additives, so that the cell amplification efficiency in the initial stage can be fully improved; a serum-free scheme is adopted for an amplification culture medium, RPMI-1640 is taken as a basic culture medium, and glutamine, rhG-CSF, bFGF, VEGF, transferrin, vitamin C, 2-mercaptoethanol, zoledronic acid, lenalidomide, ethanolamine and sodium selenite with specific amounts are added, so that the cell amplification speed in an amplification culture stage is remarkably increased. On the basis, a three-stage amplification process is adopted, and large-scale culture of the umbilical cord mesenchymal stem cells is realized. The method is short in culture time and high in cell quantity accumulation speed, and the culture efficiency is remarkably improved.

The invention provides a strain of lactobacillus plantarum ZENIYOUTH-01 and application thereof, and belongs to the technical field of probiotics and application thereof. The fermented whole grain prepared by adopting the lactobacillus plantarum disclosed by the invention effectively retains nutritional ingredients such as vitamin B, vitamin E, nicotinic acid, mineral substances and the like in the whole grain; abundant enzyme systems secreted by lactobacillus plantarum are utilized to degrade macromolecular proteins, dietary fibers and the like in the raw materials to generate bioactive peptides, short-chain fatty acids, exopolysaccharides and flavor compounds, release of functional components such as polyphenols, flavonoid compounds and the like is promoted, the contents of protein peptides, lactic acid, acetic acid, citric acid and beta-glucan are increased, and the nutritional value of the beverage is improved. The traditional Chinese medicine composition can effectively proliferate intestinal effective microbial communities and promote intestinal peristalsis, and has a remarkable effect in the aspect of improving constipation.

The present invention relates to amino acid salts of nicotinic acid mononucleotide and nicotinamide mononucleotide of formula I and compositions thereof, which can be used to treat diseases related to NAD + Deficiency-related conditions and diseases: (I), where A, M 1 、M 2 、R 1 、R 2 and R 3 As described in this article. #imgabs0#

The invention discloses a camellia antler SCR0319T2 strain and an application of the camellia antler SCR0319T2 strain. According to the invention, a strain of camellia antler SCR0319T2 is collected and screened from the field, molecular biology identification shows that the strain belongs to Flammulina filiformes, subculture shows that the strain has excellent stability, can still grow stably after more than 30 times of passage, is low in elimination rate, can be used as an industrial large-scale production strain, and is high in strain running speed and short in production period. Through detection, the content of vitamin B1 and nicotinic acid in sporocarps is higher than that of common varieties, and mushroom bodies are durable in storage and good in taste.

The invention relates to a crystal form of a free state or a pharmaceutically acceptable salt of (R)-3-(3-((S)-2-(4-(2-chlorophenoxy)-2-oxo-2, 5-dihydro-1H-pyrrole-1-yl)-4-methyl valeryl amino)-1H-pyrazole-1-yl)-2-hydroxy propyl nicotinate (compound A), a pharmaceutical composition of the crystal form and a preparation method of the crystal form. The invention also discloses application of the crystal form in preparation of medicines for treating diabetes and related symptoms.

The invention belongs to the technical field of biological medicines, and provides application of combination of nicotinic acid and metformin in blocking the progress of esophageal squamous carcinoma. The invention discovers that nicotinic acid and metformin inhibit FRMD8 expression through different mechanisms for the first time so as to inhibit a JAK1-STAT3 signal channel. Nicotinic acid and metformin are combined to achieve a more remarkable inhibition effect on the ability of esophageal squamous cell carcinoma cells to subcutaneously grow in mice and generate pulmonary metastasis through caudal veins than a single drug, and a brand new drug direction is provided for prevention and treatment of esophageal squamous cell carcinoma.

The present application relates to the technical field of organic synthesis, and particularly relates to an asymmetric preparation method of nicotine and derivatives thereof.The method of the present application takes nicotinic acid ester or substituted nicotinic acid ester and N-methyl pyrrolidone as raw materials, obtains a hydrochloride intermediate through condensation and ring-opening decarboxylation, then obtains chiral amino alcohol through asymmetric reduction, and finally obtains nicotine and analogs thereof through intramolecular ring-closing reaction.The preparation method disclosed by the present application has the advantages that raw materials are easy to obtain, operation is convenient, the process is short, the obtained product nicotine and derivatives thereof are easy to purify, and the optical purity is high.

The present invention relates to a process for producing biofertilizers / biostimulants from microalgae with intensive CO2 capture, which comprises the following steps:a) preparing an inoculum;b) cultivating for the production of microalgae biomass in a window photobioreactor;c) collecting the biomass by flocculation;d) drying the biomass, and grinding and extracting a polar fraction by solvent in a two-phase system; ande) analyzing the polar fraction by liquid chromatography.The invention also relates to the extracts of wet biomass of the microalgae Scenedesmus sp., obtaining the polar fraction. This polar fraction contains amino acids, sugars, betaine derivatives, vitamin B3 (nicotinamide or nicotinic acid) and pantothenic acid (vitamin B5), the monoterpene loliolide and the tryptophan derivative indole-lactic acid (analogous to indole-acetic acid, a phytohormone of the auxin class).The polar fraction can also be used as an input in the cultivation of soybeans, corn, sugar cane, cotton and coffee, among other cultivated species.

This disclosure relates to an embodiment of the use of tocotrienols in pharmaceutical, veterinary, or cosmetic applications, particularly in cosmetic formulations, whereby stabilizing tocotrienols does not impair their function in the skin. Specifically, this disclosure relates to the modification, molecular stabilization, and penetration properties of tocotrienols in human skin using nicotinic acid. The compounds and compositions of this subject matter are useful in the medical, veterinary, or cosmetic industries as a preventative, therapeutic, or treatment of dermatological diseases or skin disorders, as a treatment or treatment of acne or seborrheic dermatitis, or as anti-aging agents.

The present invention relates to the technical field of medicine, and disclosed a maleate of a nicotinyl alcohol ether derivative, a crystal form thereof, and an application thereof, i.e., (S)-N-(2-(pyridin-3-yl-methoxy)-4-(2-bromo-3-phenylbenzyloxy)-5-chlorobenzyl) serine isopropyl ester maleate and a stereoisomer and a crystal form thereof, a preparation method therefor, a pharmaceutical composition, and a use thereof. Specifically, the present invention relates to the (S)-N-(2-(pyridin-3-yl-methoxy)-4-(2-bromo-3-phenylbenzyloxy)-5-chlorobenzyl) serine isopropyl ester maleate represented by formula I, and a crystal form thereof, a stereoisomer thereof, a preparation method therefor, a composition containing said compound or the crystal form thereof, and a use of said compound or the crystal form thereof in the preparation of a medicine for treating diseases related to a PD-1 / PD-L1 signaling pathway, such as cancer, infectious diseases and autoimmune diseases.

An expression system for selecting the presence of a gene of interest, the expression system comprising: (i) a cell line wherein the activity of at least one enzyme in the NAD+ synthesis pathway is at least partially inhibited, the cell line optionally further comprising the gene of interest, and the cell line optionally lacking an endogenous nucleotide sequence which encodes the at least one enzyme in the NAD+ synthesis pathway; (ii) an expression vector comprising an exogenous nucleotide sequence which encodes the at least one enzyme in the NAD+ synthesis pathway; and (iii) a media formulation which does not comprise nicotinamide (NAM) and / or nicotinic acid.

The invention belongs to the field of biological medicine, and particularly relates to application of nicotinic acid and derivatives thereof in prevention or treatment of colorectal cancer growth and metastasis. It is found for the first time that nicotinic acid and novel derivatives thereof can effectively and remarkably inhibit proliferation, migration and invasion of colorectal cancer cells, and can inhibit growth and liver metastasis of the colorectal cancer cells in a mouse model. Experiments prove that the medicine reagent prepared from the nicotinic acid or the combination of the nicotinic acid and other medicines is safe and effective, and a new thought is provided for preparing the medicines for preventing or treating the liver cancer.

The present invention relates to an improved process for preparation of Zastaprazan or its pharmaceutically acceptable salts, which comprises: a) reaction of methyl 5,6- diaminonicotinate and 3-bromobutan-2-one to obtain methyl 8-amino-2,3-dimethyl imidazo[1,2-a]pyridine-6-carboxylate hydrobromide salt, b) reaction of obtained compound in step a) with 2,6-dimethylbenzyl chloride in presence of base in solvent, in absence of catalyst to obtain methyl 8-((2,6-dimethylbenzyl)amino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate, c) hydrolysis of the obtained compound in step b) in presence of base in a solvent to obtain 8-((2,6-dimethylbenzyl)amino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid d) condensation of obtained compound in step c) with azetidine or its salts in presence of condensing agent, base and solvent to obtain Zastaprazan, wherein condensing agent is selected from PyBOP or T3P.

The application discloses an aspartate ligase mutant and application thereof in production of nicotinamide, and belongs to the technical field of enzyme engineering. The aspartate ligase mutant is obtained by mutation on the basis of wild-type aspartate ligase shown in SEQ ID NO. 5, and at least includes the 104th site. The aspartate ligase mutant has higher catalytic activity in catalyzing synthesis of nicotinamide from nicotinic acid, and can significantly improve the production efficiency of nicotinamide. Coupling of the aspartate ligase mutant with polyphosphate phosphate transferase can also realize ATP cycle regeneration, reduce the addition amount of ATP, and further greatly reduce the preparation cost of nicotinamide. Therefore, the mutant is suitable for industrial production, and has good application prospect.

The invention relates to cosmetics. [Problem] To provide a cosmetic having an excellent feeling of use. [Solution] A cosmetic containing: (A) at least one of (a-1) nicotinic acid or a derivative thereof, (a-2) a pyrimidine pyrazole compound having a specific structure or a salt thereof, or (a-3) a cyclic formamide derivative having a specific structure or a salt thereof; (B) agar; (C) succinyl glycan; and (D) water.

The present invention relates to the free state of (R)-3-(3-((S)-2-(4-(2-chlorophenoxy)-2-oxo-2,5-dihydro-1H-pyrrole-1-yl)-4-methylpentanoylamino)-1H-pyrazole-1-yl)-2-hydroxypropylnicotinate (compound A) or crystalline forms of its pharmaceutically acceptable salts, pharmaceutical compositions and methods for preparing the same, and the use of the above crystalline form in the preparation of pharmaceuticals for the treatment of diabetes and related conditions. [C1] TIFF2026511448000095.tif36156

The invention relates to a quantitative analysis method of nicotinic acid and nicotinamide in tobacco leaves, which comprises the following steps: 1) sample pretreatment: accurately weighing a tobacco leaf sample, adding a mixed solvent of methanol, water and dichloromethane, carrying out oscillation extraction and centrifugal treatment, taking supernatant liquid, and carrying out freeze drying treatment to obtain freeze-dried residues; adding pyridine and BSTFA into the freeze-dried residues to carry out silanization derivation reaction to form a nicotinic acid derivative and a nicotinamide derivative, namely a sample to be detected; 2) preparing a standard solution and drawing a standard curve; 3) sample analysis: performing gas chromatography-mass spectrometry analysis on the to-be-detected sample to obtain chromatographic peaks and mass spectrum peaks of the derivatives of nicotinic acid and nicotinamide; and according to the retention time of the chromatographic peak and mass spectrum characteristic ion peak qualitative analysis, the content of nicotinic acid and nicotinamide in the tobacco leaf sample is calculated through external standard method quantitative analysis. The quantitative analysis method is simple, convenient, efficient and high in sensitivity and accuracy.

Disclosed are novel prodrugs derived from nicotinic acid and pharmaceutical compositions thereof which may be used to treat or prevent a variety of medical disorders, which may be characterized by mitochondrial dysfunction. The compounds and pharmaceutical compositions thereof may be used to treat or prevent metabolic disorders, cardiovascular disorders, cerebrovascular disorders, liver disorders, a kidney disorders or muscle disorders.